Skip to content
‹ Back to IndustriesHealthcare

Unlocking Your Body’s Ability to Fight Cancer

The common saying, “You are what you eat,” may indeed be true. Consuming unhealthy food and beverages can put you at increased risk for developing chronic health conditions, obesity, and even 13 types of cancer, according to the Centers for Disease Control and Prevention (CDC). While this may seem disheartening, new research shows that nutritional…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Promoted content from Highway to Health on MarketScale.

·
Share

Free workspace

Turn your Healthcare expertise into content.

Record interviews, organize footage, and write with AI on a free trial of the MarketScale platform for qualifying companies. No demo required, no credit card.

Try it Free

The common saying, “You are what you eat,” may indeed be true. Consuming unhealthy food and beverages can put you at increased risk for developing chronic health conditions, obesity, and even 13 types of cancer, according to the Centers for Disease Control and Prevention (CDC). While this may seem disheartening, new research shows that nutritional consumption can influence how cancer patients respond to treatments such as radiation and chemotherapy.

How, exactly, can nutritional intake play into the molecular responsiveness of cancers to change the efficacy of cancer treatments and help save lives?

On today’s episode of Highway to Health, host David Kemp speaks with Virginia Casadas, VP, Head of Clinical Operations at Faeth, and Oliver Maddocks, Co-Founder and Head of Research at Faeth, to talk about the premise of their company and the clinical trials they are currently involved in to further examine nutrition in the context of sensitivity to cancer treatments.

Kemp, Casadas, and Maddocks also discussed…

  1. Who Faeth is and the cancers Faeth has identified might be most receptive to nutrient control
  2. The clinical trials Faeth currently has and what they are looking at with the trials
  3. How Faeth is delivering guidance to patients through their app

Maddocks explained how nutrient control can impact responsiveness to other cancer treatments: “If you, as the patient, can control the nutrient levels to the tumor, you can kind of change that balance and increase the sensitivity and the efficacy.” He added, “The exact type of tumor that you have and the genotype makes a big contribution to what that tumor needs the most in terms of its nutrients. What we’re trying to do is understand the nutrient needs of tumors at that molecular level and then design diets that are really precisely controlled.”

Casadas elaborated on how Faeth’s clinical trials are capitalizing on controlled nutrition to improve cancer treatment outcomes. “Right now, in terms of the technology that’s used in the context of the trial, it’s with our registered dieticians and somewhat prescriptive by protocol.”

Virginia Casadas is the VP and Head of Clinical Operations at Faeth. She has previously served as Director of Clinical Operations at Stealth Biotech Startup and Vir Biotechnology, Inc., amongst other pharmaceutical and clinical roles. Casadas earned a BS in Biology from the University of Illinois at Urbana-Champaign, a Master of Science in Health Care Management from Saint Elizabeth University, and a Master’s Certificate in Applied Project from Villanova University.

Oliver Maddocks is co-founder and head of research at Faeth and a professor and group leader at the University of Glasgow. He was also a postdoctoral scientist and Fulbright Scholar at the University of Maryland School of Medicine. Maddocks holds an MPharm in pharmacy from Cardiff University and a Ph.D. in cancer molecular biology from the University of Edinburgh. He currently has 30 scientific publications.

Highway to Health

Part of this channel

Highway to Health

Healthcare innovation conversations for executives and technology buyers.

Visit the channel

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Book DemoSee how it works15 minutes, straight to a calendar.
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free Trial

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Start a free trial and see it with your own people. For qualifying companies, no credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What your free trial includes

Hands-on access to the MarketScale platform
Media requests to your crowd, remote recording, AI writing tools
No demo required. No credit card.
For qualifying companies. Company confirmation required.

More Healthcare Insights

Why hospitals stagger security upgrades instead of shutting down

Why hospitals stagger security upgrades instead of shutting down

Parabit Systems' Robert Iraggi told A Weekly Bit that hospital security upgrades must be planned and staggered because the building never closes. OSHA counted 7.8 serious violent injuries per 10,000 healthcare workers in 2013 against under two in construction, and Joint Commission EP 17 requires an annual worksite analysis. Illinois biometric law adds a consent step for facial recognition.

  • 01OSHA counted 7.8 serious violent injuries per 10,000 healthcare workers in 2013; construction, manufacturing and retail each stayed under two.
  • 02Joint Commission EP 17 has required an annual workplace violence worksite analysis since January 2022, and hospitals are expected to act on what it finds—making phased security upgrades easier to document year to year.
  • 03Squire Patton Boggs counted at least 100 Illinois biometric privacy class actions filed in 2025, and Illinois’ BIPA requires notice and consent for collecting biometrics—so a facial-recognition rollout plan should include the notice, consent record, and retention controls before the first camera goes live.

Nov 17, 2026

Sterile processing deviations become the norm without stop-and-document rules

Sterile processing deviations become the norm without stop-and-document rules

Advanced Sterilization Products' Tamara Beeler told Censis Technologies' CtUC 2026 audience that sterile processing deviations harden into norms when departments don’t stop, escalate and document them. She connects ANSI/AAMI ST108:2023 water categories, daily cleaning verification, loaner-tray refusal when sets arrive late or lack IFUs, and root cause analysis when rework repeats on the same device.

  • 01ANSI/AAMI ST108:2023 turned water quality for instrument reprocessing into an enforceable standard; AAMI's earlier TIR34 was guidance with no enforcement behind it.
  • 02Some facilities require loaner trays 48 hours before a case, and ASP's Tamara Beeler says a technician at any level can refuse one that arrives late, undocumented or dirty.
  • 03Rework that returns on the same device is the point at which Beeler wants a root cause analysis opened, with the record kept in the instrument tracking system.

Nov 17, 2026

TheraPanacea aims to spread best-center radiotherapy quality

TheraPanacea aims to spread best-center radiotherapy quality

TheraPanacea CEO Nikos Paragios says the company's two objectives are to carry best-center radiotherapy quality to every patient and to pick each patient's treatment at the start from multimodal data. A 2026 Nature Communications trial of 500 patients found AI-assisted contouring lifted mean Dice overlap from 0.857 to 0.902, and Siemens Healthineers CE-marked its own AI contouring in May 2026.

  • 01TheraPanacea's two stated objectives: carry best-center radiotherapy quality to every patient on the globe, and identify each patient's best treatment at the start from imaging and clinical history.
  • 02A 2026 Nature Communications trial of 500 patients across five centers found AI-assisted contouring lifted mean Dice overlap from 0.857 to 0.902 and cut median contouring time from 55 to 10 minutes, with less variation between centers.
  • 03Siemens Healthineers' Varian business CE-marked AI contouring for Eclipse in May 2026, so Paragios locates TheraPanacea's edge in its team, hospital partnerships and impact focus rather than in the algorithm alone.

Nov 17, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a Demo

Or call us. No forms required. We pick up. 214-945-2512